INmune Bio Targets UK Ebstrocel Approval in Mid-2027

Bitget2026/10/21 11:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

INmune Bio targets an early February 2027 UK approval application for Ebstrocel, its investigational therapy for recessive dystrophic epidermolysis bullosa.
Potential UK approval in mid-2027 could come approximately six weeks earlier under the revised submission strategy.
A US biologics license application is planned for the second quarter of 2027, subject to FDA meeting feedback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210715PRIMZONEFULLFEED9849919) on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

INmune Bio Targets UK Ebstrocel Approval in Mid-2027

You may also like

Crypto prices